SALT LAKE CITY , Oct. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced offering of 12,727,272 shares of common stock (or pre-funded warrants in-lieu thereof) at an offering price of $0.55 per share (the "Offering").

The gross proceeds to the Company from the Offering were approximately $7.0 million before deducting the placement agent's fees and other offering expenses. The Company intends to use proceeds from the Offering for working capital and general corporate purposes.

Maxim Group LLC acted as the sole placement agent in connection with the Offering.

The securities w

See Full Page